ResMed is a wide-moat medical devices company with a perfect Piotroski F-Score of 9 out of 9, 25% return on equity, and four consecutive earnings beats, currently experiencing a technical downtrend that creates an accumulation opportunity for investors with a 12-to-18 month horizon.
Thesis pillars
- Wide Moat Compounder Quality→Stable
- Perfect Earnings Beat Streak↑Improving
- Technical Downtrend Accumulation Window↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
ResMed Inc. (RMD) Stock Analysis
Range Bound setup · Temporary headwind edge
Healthcare · Medical Instruments & Supplies
Wait for pullback to $213.55. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $228.50. Engine's entry $213.55 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining.
ResMed designs and manufactures digital health technologies and cloud-connected medical devices — including CPAP, bilevel, and ventilation systems — to treat sleep apnea, COPD, and other chronic respiratory diseases, across two segments: Sleep and Breathing Health and... Read more
Wait for pullback to $213.55. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $228.50. Engine's entry $213.55 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: RSI 56 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Score 5.7/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news boost analyst 0.70, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About ResMed Inc.
About ResMed Inc.
ResMed operates two segments, Sleep and Breathing Health and Residential Care Software, selling cloud-connected devices such as CPAP and AirCurve 11 Series bilevel systems alongside patient-engagement software including myAir and AirView. The installed base spans more than 30 million AirView patients and more than 10 million myAir users, while Residential Care Software supports more than 160 million patient accounts. Sales outside the U.S. represented approximately 36% of net revenue in both fiscal 2025 and 2024.
ResMed generates revenue primarily through device sales — CPAP, bilevel, high-flow therapy, and ventilator systems along with masks, headgear, and accessories — distributed through wholly owned subsidiaries and independent distributors to dealers of home healthcare products, sleep clinics, and physicians, supplemented by recurring cloud-services and software revenue from its Residential Care Software platforms serving HME, home infusion, skilled nursing, senior living, and hospice providers. The company manufactures substantially all of its products outside the United States while selling into more than 140 countries, and it depends on third-party and government payors, including Medicare and international reimbursement schemes, to cover patient therapy costs. Growth investments include the April 2025 nationwide rollout of its NightOwl home sleep apnea test and the May 2025 acquisition of VirtuOx, an independent diagnostic testing facility that expands ResMed's in-home diagnostics and patient-monitoring capabilities.
Show full overview
A structural exposure sits outside the product portfolio: ResMed manufactures substantially all of its products outside the United States even as sales remain majority U.S.-sourced, leaving the company's cost base tied to newly imposed and threatened U.S. tariffs on a wide variety of imported goods, plus retaliatory tariffs other countries have imposed or are considering on U.S. exports. The 10-K also flags the Uyghur Forced Labor Prevention Act's import restrictions and potential supply disruption tied to the Russia-Ukraine and Israel-Iran conflicts as risks to its suppliers' ability to source raw materials, though it states combined device sales into Iran, Russia, and Ukraine were not material to fiscal 2025 revenue.
See also: Healthcare · Medical Instruments & Supplies
From ResMed Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-09-04Recent Developments — ResMed Inc.
Latest news
- NEWS ResMed (RMD) Could Be 14% Undervalued On Its Sleep Health Growth Story - simplywall.st — simplywall.st positive
- NEWS ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch — MarketWatch positive
- NEWS ResMed Inc. stock rises Wednesday, outperforms market - marketwatch.com — marketwatch.com positive
- NEWS BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $320 - Moomoo — Moomoo positive
- NEWS ResMed (RMD) Q2 2026 Earnings: EPS Beats Estimates, Stock Rises 2.9% - EPS Miss Report - dars.gov.et — dars.gov.et positive
Generated 2026-09-04T12:07:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicEurope, Asia and other regions36%10-K Item 1A: 'Sales in combined Europe, Asia and other regions accounted for approximately 36% and 36% of our net revenues in the ... years ended June 30, 2025 and June 30, 2024, respectively.'
- HIGHGeographicmanufacturing outside the U.S.10-K Item 1A: 'We manufacture substantially all of our products outside the U.S.'
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMCFO Brett Sandercock retires effective May 4, 2026, becoming Special Advisor through 2027; succeeded by Aaron Bloomer (ex-Exact Sciences CFO). No disagreement with the company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $213.55. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $228.50. Engine's entry $213.55 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: RSI 56 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Target $237.55 (+4.0%), stop $200.85 (−13.8%), A.R:R -0.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $237.55 (-3.3% upside). Target $237.55 (+4.0%), stop $200.85 (−13.8%), A.R:R -0.3:1. Stop-loss: $200.85.
Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining; Weak growth.
ResMed Inc. trades at a P/E of 22.1 (forward 17.3). TrendMatrix value score: 5.3/10. Verdict: Buy (Wait for Entry).
27 analysts cover RMD with a consensus score of 3.5/5. Average price target: $246.
What does ResMed Inc. do?ResMed designs and manufactures digital health technologies and cloud-connected medical devices — including CPAP,...
ResMed designs and manufactures digital health technologies and cloud-connected medical devices — including CPAP, bilevel, and ventilation systems — to treat sleep apnea, COPD, and other chronic respiratory diseases, across two segments: Sleep and Breathing Health and Residential Care Software. The company employs more than 10,600 people, sells in more than 140 countries, and supports an installed base of more than 30 million cloud-connected patients.